| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 53 | 2025 | 1147 | 4.320 |
Why?
|
| Kidney Transplantation | 12 | 2023 | 558 | 1.740 |
Why?
|
| Tissue Donors | 19 | 2024 | 506 | 1.630 |
Why?
|
| End Stage Liver Disease | 12 | 2024 | 193 | 1.450 |
Why?
|
| Graft Survival | 28 | 2024 | 465 | 1.380 |
Why?
|
| Graft Rejection | 12 | 2025 | 552 | 1.330 |
Why?
|
| Waiting Lists | 14 | 2024 | 253 | 1.190 |
Why?
|
| Tissue and Organ Procurement | 11 | 2022 | 254 | 1.110 |
Why?
|
| Donor Selection | 6 | 2024 | 60 | 1.040 |
Why?
|
| Liver Failure | 6 | 2017 | 99 | 1.010 |
Why?
|
| Transplant Recipients | 6 | 2022 | 235 | 0.690 |
Why?
|
| Liver Neoplasms | 10 | 2022 | 1373 | 0.570 |
Why?
|
| Food Handling | 1 | 2018 | 14 | 0.550 |
Why?
|
| Child, Preschool | 33 | 2025 | 15110 | 0.460 |
Why?
|
| Retrospective Studies | 38 | 2025 | 17753 | 0.450 |
Why?
|
| Cystic Fibrosis | 2 | 2020 | 268 | 0.440 |
Why?
|
| Postoperative Complications | 9 | 2020 | 3147 | 0.430 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2021 | 1071 | 0.430 |
Why?
|
| Infant | 26 | 2025 | 13352 | 0.400 |
Why?
|
| Child | 36 | 2025 | 26341 | 0.380 |
Why?
|
| Caroli Disease | 1 | 2012 | 1 | 0.370 |
Why?
|
| Adolescent | 30 | 2025 | 20987 | 0.360 |
Why?
|
| Survival Rate | 14 | 2022 | 2114 | 0.360 |
Why?
|
| Humans | 82 | 2025 | 131163 | 0.360 |
Why?
|
| Immunosuppressive Agents | 4 | 2025 | 663 | 0.360 |
Why?
|
| Kidney Failure, Chronic | 4 | 2022 | 934 | 0.350 |
Why?
|
| Age Factors | 8 | 2024 | 2825 | 0.340 |
Why?
|
| Death | 1 | 2012 | 78 | 0.340 |
Why?
|
| Treatment Outcome | 24 | 2024 | 12936 | 0.340 |
Why?
|
| Brain Death | 1 | 2012 | 73 | 0.340 |
Why?
|
| Transplantation, Homologous | 7 | 2018 | 670 | 0.330 |
Why?
|
| Risk Factors | 20 | 2024 | 11074 | 0.330 |
Why?
|
| Seasons | 1 | 2012 | 335 | 0.320 |
Why?
|
| Male | 52 | 2025 | 64957 | 0.310 |
Why?
|
| Length of Stay | 4 | 2020 | 1421 | 0.310 |
Why?
|
| Vascular Grafting | 3 | 2019 | 51 | 0.310 |
Why?
|
| Transforming Growth Factor beta | 4 | 2003 | 451 | 0.300 |
Why?
|
| Ureteral Obstruction | 2 | 2023 | 88 | 0.300 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2011 | 77 | 0.300 |
Why?
|
| Organ Transplantation | 3 | 2020 | 175 | 0.300 |
Why?
|
| Ureter | 2 | 2023 | 84 | 0.300 |
Why?
|
| Body Weight | 2 | 2019 | 987 | 0.300 |
Why?
|
| Databases, Factual | 3 | 2018 | 1240 | 0.300 |
Why?
|
| Follow-Up Studies | 15 | 2022 | 5196 | 0.290 |
Why?
|
| Fellowships and Scholarships | 1 | 2012 | 327 | 0.290 |
Why?
|
| Adult | 30 | 2024 | 31282 | 0.280 |
Why?
|
| Plasminogen | 2 | 1998 | 7 | 0.280 |
Why?
|
| Female | 49 | 2025 | 70963 | 0.270 |
Why?
|
| Patient Selection | 4 | 2020 | 729 | 0.260 |
Why?
|
| Adenoma | 1 | 2008 | 144 | 0.250 |
Why?
|
| Decision Support Techniques | 3 | 2019 | 293 | 0.250 |
Why?
|
| Severity of Illness Index | 6 | 2024 | 3061 | 0.240 |
Why?
|
| Kidney | 4 | 2021 | 1282 | 0.240 |
Why?
|
| Carcinoma | 1 | 2008 | 291 | 0.240 |
Why?
|
| Sarcoma | 1 | 2008 | 219 | 0.240 |
Why?
|
| Hepatoblastoma | 2 | 2020 | 204 | 0.230 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2022 | 982 | 0.230 |
Why?
|
| Heart Transplantation | 3 | 2022 | 800 | 0.230 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 1410 | 0.230 |
Why?
|
| Middle Aged | 22 | 2024 | 28601 | 0.230 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 59 | 0.210 |
Why?
|
| Allografts | 6 | 2021 | 220 | 0.210 |
Why?
|
| Peptide Fragments | 2 | 1998 | 687 | 0.210 |
Why?
|
| United States | 13 | 2024 | 12072 | 0.200 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2016 | 89 | 0.200 |
Why?
|
| Venous Thrombosis | 2 | 2023 | 164 | 0.200 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 2003 | 63 | 0.200 |
Why?
|
| Sirolimus | 1 | 2025 | 230 | 0.200 |
Why?
|
| Isoenzymes | 3 | 2003 | 211 | 0.190 |
Why?
|
| Models, Theoretical | 2 | 2015 | 362 | 0.190 |
Why?
|
| Time Factors | 11 | 2024 | 6196 | 0.180 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2023 | 79 | 0.180 |
Why?
|
| Internship and Residency | 1 | 2012 | 1223 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 2 | 1998 | 740 | 0.180 |
Why?
|
| Iliac Vein | 2 | 2019 | 24 | 0.180 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2022 | 34 | 0.180 |
Why?
|
| Logistic Models | 4 | 2021 | 1797 | 0.180 |
Why?
|
| Infant, Newborn | 11 | 2021 | 8635 | 0.170 |
Why?
|
| Tissue Banks | 2 | 2011 | 27 | 0.170 |
Why?
|
| Young Adult | 11 | 2022 | 10103 | 0.170 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 314 | 0.170 |
Why?
|
| Critical Care | 2 | 2017 | 686 | 0.170 |
Why?
|
| Body Mass Index | 2 | 2018 | 1717 | 0.160 |
Why?
|
| Cause of Death | 4 | 2019 | 506 | 0.160 |
Why?
|
| Aged | 12 | 2024 | 21025 | 0.160 |
Why?
|
| Cystinosis | 1 | 2020 | 16 | 0.160 |
Why?
|
| Learning Curve | 1 | 2020 | 54 | 0.150 |
Why?
|
| Transplantation | 1 | 2019 | 24 | 0.150 |
Why?
|
| Survival Analysis | 4 | 2019 | 1483 | 0.150 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2010 | 28 | 0.150 |
Why?
|
| Multivariate Analysis | 4 | 2021 | 1378 | 0.150 |
Why?
|
| Intestinal Neoplasms | 1 | 1999 | 36 | 0.150 |
Why?
|
| Health Facilities | 1 | 2019 | 66 | 0.150 |
Why?
|
| Hepatic Artery | 1 | 2019 | 45 | 0.140 |
Why?
|
| Liver | 6 | 2021 | 1796 | 0.140 |
Why?
|
| Iliac Artery | 1 | 2019 | 63 | 0.140 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 93 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 315 | 0.140 |
Why?
|
| HLA Antigens | 2 | 2013 | 221 | 0.140 |
Why?
|
| Prognosis | 10 | 2020 | 4886 | 0.140 |
Why?
|
| Celiac Artery | 1 | 2018 | 32 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2020 | 217 | 0.140 |
Why?
|
| Ireland | 1 | 2018 | 33 | 0.140 |
Why?
|
| Sodium, Dietary | 1 | 2018 | 31 | 0.140 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 133 | 0.140 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2018 | 38 | 0.140 |
Why?
|
| Dietary Sugars | 1 | 2018 | 19 | 0.140 |
Why?
|
| Portal Vein | 1 | 2018 | 84 | 0.140 |
Why?
|
| Cold Ischemia | 1 | 2018 | 29 | 0.130 |
Why?
|
| Blood Loss, Surgical | 1 | 2019 | 168 | 0.130 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 146 | 0.130 |
Why?
|
| Precision Medicine | 2 | 2011 | 388 | 0.130 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2017 | 8 | 0.130 |
Why?
|
| Ectodermal Dysplasia | 1 | 2017 | 62 | 0.130 |
Why?
|
| Hemangioendothelioma | 2 | 2007 | 24 | 0.130 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 36 | 0.130 |
Why?
|
| Nutrition Assessment | 1 | 2018 | 126 | 0.130 |
Why?
|
| Pandemics | 2 | 2022 | 1118 | 0.120 |
Why?
|
| Autoantibodies | 2 | 2013 | 451 | 0.120 |
Why?
|
| Reoperation | 2 | 2018 | 818 | 0.120 |
Why?
|
| Acute Disease | 2 | 2016 | 1153 | 0.120 |
Why?
|
| Drowning | 1 | 2017 | 48 | 0.120 |
Why?
|
| Dietary Fats | 1 | 2018 | 278 | 0.120 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2017 | 72 | 0.120 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 1826 | 0.120 |
Why?
|
| Nutrition Surveys | 1 | 2018 | 338 | 0.120 |
Why?
|
| Blood Group Incompatibility | 1 | 2016 | 28 | 0.120 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 61 | 0.120 |
Why?
|
| Perfume | 1 | 2015 | 2 | 0.110 |
Why?
|
| Cosmetics | 1 | 2015 | 11 | 0.110 |
Why?
|
| Craniosynostoses | 1 | 2017 | 146 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2018 | 377 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2021 | 722 | 0.110 |
Why?
|
| Lung Transplantation | 1 | 2020 | 363 | 0.110 |
Why?
|
| Bone and Bones | 1 | 2017 | 308 | 0.110 |
Why?
|
| Energy Intake | 1 | 2018 | 502 | 0.110 |
Why?
|
| Biliary Atresia | 1 | 2018 | 223 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2022 | 5063 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2017 | 483 | 0.110 |
Why?
|
| Endpoint Determination | 1 | 2015 | 58 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 239 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 789 | 0.110 |
Why?
|
| Genome, Human | 2 | 2011 | 1321 | 0.100 |
Why?
|
| Living Donors | 3 | 2022 | 111 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2011 | 587 | 0.100 |
Why?
|
| Transplants | 2 | 2018 | 38 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 889 | 0.100 |
Why?
|
| Aspergillus fumigatus | 1 | 2013 | 41 | 0.100 |
Why?
|
| Aspergillosis | 1 | 2013 | 43 | 0.090 |
Why?
|
| Isoantibodies | 1 | 2013 | 59 | 0.090 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 108 | 0.090 |
Why?
|
| Hospitalization | 2 | 2020 | 1950 | 0.090 |
Why?
|
| Immunoassay | 1 | 2013 | 126 | 0.090 |
Why?
|
| Disease Progression | 4 | 2020 | 2200 | 0.090 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2016 | 729 | 0.090 |
Why?
|
| Environmental Exposure | 1 | 2015 | 298 | 0.090 |
Why?
|
| Schools, Medical | 1 | 2013 | 113 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2016 | 564 | 0.090 |
Why?
|
| Hospitals, Pediatric | 2 | 2016 | 808 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2020 | 214 | 0.090 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2012 | 59 | 0.090 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2011 | 41 | 0.090 |
Why?
|
| Incidence | 3 | 2019 | 3360 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2024 | 3711 | 0.090 |
Why?
|
| Renal Veins | 2 | 2023 | 31 | 0.080 |
Why?
|
| Urokinase-Type Plasminogen Activator | 3 | 2003 | 32 | 0.080 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2011 | 53 | 0.080 |
Why?
|
| Diet | 1 | 2018 | 1121 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2015 | 385 | 0.080 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2009 | 103 | 0.080 |
Why?
|
| Anus Neoplasms | 1 | 2010 | 40 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 198 | 0.080 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2009 | 10 | 0.080 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 221 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 712 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 6797 | 0.080 |
Why?
|
| Cystadenoma | 1 | 2009 | 1 | 0.070 |
Why?
|
| Postoperative Period | 2 | 2020 | 331 | 0.070 |
Why?
|
| Databases, Genetic | 1 | 2011 | 504 | 0.070 |
Why?
|
| Angiostatins | 2 | 1998 | 3 | 0.070 |
Why?
|
| Sepsis | 1 | 2013 | 493 | 0.070 |
Why?
|
| Anastomosis, Surgical | 2 | 2019 | 176 | 0.070 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 1998 | 38 | 0.070 |
Why?
|
| Texas | 2 | 2016 | 3686 | 0.070 |
Why?
|
| Registries | 1 | 2015 | 1634 | 0.070 |
Why?
|
| Propionates | 1 | 2006 | 31 | 0.060 |
Why?
|
| Global Health | 1 | 2012 | 626 | 0.060 |
Why?
|
| Hepatitis C | 2 | 2011 | 381 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 1998 | 975 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 2011 | 631 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2008 | 245 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2009 | 319 | 0.060 |
Why?
|
| Epoprostenol | 1 | 2006 | 33 | 0.060 |
Why?
|
| Cholangiocarcinoma | 1 | 2007 | 126 | 0.060 |
Why?
|
| Bile Duct Neoplasms | 1 | 2007 | 130 | 0.060 |
Why?
|
| Hypothyroidism | 1 | 2006 | 71 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 3 | 2003 | 121 | 0.060 |
Why?
|
| Hypertension, Portal | 1 | 2006 | 78 | 0.060 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2006 | 115 | 0.060 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2005 | 28 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2016 | 1272 | 0.060 |
Why?
|
| Pediatrics | 2 | 2019 | 1252 | 0.050 |
Why?
|
| Diabetic Neuropathies | 1 | 2005 | 56 | 0.050 |
Why?
|
| Parenteral Nutrition | 1 | 2006 | 219 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 750 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2006 | 273 | 0.050 |
Why?
|
| Diabetic Retinopathy | 1 | 2005 | 75 | 0.050 |
Why?
|
| Viral Load | 1 | 2005 | 416 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 414 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 2304 | 0.050 |
Why?
|
| Suction | 1 | 2023 | 48 | 0.050 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 289 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2005 | 638 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2003 | 232 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2023 | 117 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 457 | 0.040 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2021 | 49 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 2 | 2011 | 70 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1129 | 0.040 |
Why?
|
| Protective Factors | 1 | 2021 | 91 | 0.040 |
Why?
|
| Cysteamine | 1 | 2020 | 16 | 0.040 |
Why?
|
| Gallbladder | 1 | 2020 | 18 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2020 | 100 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 235 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 210 | 0.040 |
Why?
|
| Forecasting | 2 | 2011 | 351 | 0.040 |
Why?
|
| Cytokines | 1 | 2006 | 1339 | 0.040 |
Why?
|
| Rats | 3 | 2003 | 3370 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2011 | 3436 | 0.040 |
Why?
|
| Anatomic Variation | 1 | 2019 | 3 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 1618 | 0.040 |
Why?
|
| Neutropenia | 1 | 2020 | 209 | 0.040 |
Why?
|
| Rituximab | 1 | 2020 | 170 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 613 | 0.040 |
Why?
|
| Tetrazoles | 1 | 2019 | 70 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 223 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 190 | 0.040 |
Why?
|
| Aprotinin | 1 | 1998 | 9 | 0.040 |
Why?
|
| Culture Media, Serum-Free | 1 | 1998 | 23 | 0.030 |
Why?
|
| Plasminogen Activators | 1 | 1998 | 17 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2019 | 123 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1998 | 49 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 1999 | 111 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2003 | 771 | 0.030 |
Why?
|
| Operative Time | 1 | 2019 | 201 | 0.030 |
Why?
|
| United Kingdom | 1 | 2019 | 267 | 0.030 |
Why?
|
| Sulfones | 1 | 1998 | 72 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2003 | 2885 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 219 | 0.030 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 58 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2021 | 282 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 786 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 761 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 1998 | 227 | 0.030 |
Why?
|
| Antibodies | 1 | 1998 | 322 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1999 | 645 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 895 | 0.030 |
Why?
|
| Blotting, Western | 1 | 1998 | 1013 | 0.030 |
Why?
|
| Age Distribution | 2 | 2007 | 422 | 0.030 |
Why?
|
| Aorta | 1 | 2019 | 521 | 0.030 |
Why?
|
| Craniocerebral Trauma | 1 | 2017 | 144 | 0.030 |
Why?
|
| Consumer Product Safety | 1 | 2015 | 29 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 387 | 0.030 |
Why?
|
| Intestines | 1 | 1999 | 587 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 1999 | 905 | 0.030 |
Why?
|
| Thrombosis | 1 | 2019 | 499 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 726 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 365 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 526 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 400 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 226 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1216 | 0.020 |
Why?
|
| Indicator Dilution Techniques | 1 | 2013 | 24 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2013 | 164 | 0.020 |
Why?
|
| Critical Illness | 1 | 2017 | 630 | 0.020 |
Why?
|
| Deltaretrovirus Infections | 1 | 2011 | 6 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2904 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1998 | 972 | 0.020 |
Why?
|
| Jaundice, Obstructive | 1 | 2010 | 5 | 0.020 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2010 | 10 | 0.020 |
Why?
|
| Jejunostomy | 1 | 2010 | 21 | 0.020 |
Why?
|
| Pancreatic Ducts | 1 | 2010 | 20 | 0.020 |
Why?
|
| Minority Groups | 1 | 2013 | 260 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 129 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2010 | 73 | 0.020 |
Why?
|
| Bile Ducts | 1 | 2010 | 52 | 0.020 |
Why?
|
| Epigenomics | 1 | 2011 | 181 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 224 | 0.020 |
Why?
|
| Epithelium | 1 | 2010 | 335 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2011 | 224 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 563 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2011 | 211 | 0.020 |
Why?
|
| Cadaver | 1 | 2009 | 114 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1336 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 1489 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2010 | 6459 | 0.020 |
Why?
|
| Exome | 1 | 2011 | 1061 | 0.020 |
Why?
|
| Remission Induction | 1 | 2006 | 306 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2005 | 152 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 531 | 0.010 |
Why?
|
| C-Peptide | 1 | 2005 | 107 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2005 | 185 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2005 | 151 | 0.010 |
Why?
|
| Animals | 3 | 2003 | 33912 | 0.010 |
Why?
|
| Prevalence | 1 | 2011 | 2701 | 0.010 |
Why?
|
| Survivors | 1 | 2007 | 344 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 903 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2005 | 259 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2005 | 448 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1833 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2006 | 247 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 358 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 2026 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1882 | 0.010 |
Why?
|
| Fibrinolysin | 1 | 2003 | 9 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2003 | 159 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2003 | 47 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 824 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2003 | 42 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 1205 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2003 | 308 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2003 | 142 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2006 | 499 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2065 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 1345 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2003 | 349 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2005 | 807 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1999 | 92 | 0.010 |
Why?
|
| Cell Count | 1 | 1999 | 212 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 1680 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2552 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1999 | 242 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 718 | 0.010 |
Why?
|
| Apoptosis | 1 | 1999 | 1827 | 0.010 |
Why?
|
| Phenotype | 1 | 1999 | 4497 | 0.000 |
Why?
|